Radius Pharmaceuticals Announces Licensing Agreement with Pharmanovia to Register and Commercialize Abaloparatide in China and Select Asia Pacific Territories
Radius Pharmaceuticals has announced a licensing agreement with Pharmanovia for the commercialization of abaloparatide, a bone-forming agent for osteoporosis treatment, in key Asia Pacific markets. The agreement covers China and nine other territories including Singapore, Thailand, Indonesia, Vietnam, Taiwan, Hong Kong, Malaysia, Macau, and the Philippines.
The drug, marketed as TYMLOS® in the U.S., is indicated for treating osteoporosis in postmenopausal women and men at increased risk of fractures. Under the agreement terms, Radius will receive an upfront payment, regulatory and commercial milestones, plus tiered royalties on net sales.
The partnership aims to leverage Pharmanovia's strong commercial presence in APAC, particularly in China, where they maintain a leading osteoporosis commercial platform.
Radius Pharmaceuticals ha annunciato un accordo di licenza con Pharmanovia per la commercializzazione di abaloparatide, un agente osteogenico per il trattamento dell'osteoporosi, nei principali mercati dell'Asia Pacifico. L'accordo copre la Cina e nove altri territori, tra cui Singapore, Thailandia, Indonesia, Vietnam, Taiwan, Hong Kong, Malesia, Macao e Filippine.
Il farmaco, commercializzato come TYMLOS® negli Stati Uniti, è indicato per il trattamento dell'osteoporosi nelle donne in postmenopausa e negli uomini a maggior rischio di fratture. In base ai termini dell'accordo, Radius riceverà un pagamento iniziale, traguardi normativi e commerciali, oltre a royalty scaglionate sulle vendite nette.
La partnership mira a sfruttare la forte presenza commerciale di Pharmanovia nell'APAC, in particolare in Cina, dove mantengono una piattaforma commerciale leader per l'osteoporosi.
Radius Pharmaceuticals ha anunciado un acuerdo de licencia con Pharmanovia para la comercialización de abaloparatide, un agente formador de hueso para el tratamiento de la osteoporosis, en los principales mercados de Asia-Pacífico. El acuerdo abarca China y otros nueve territorios, incluyendo Singapur, Tailandia, Indonesia, Vietnam, Taiwán, Hong Kong, Malasia, Macao y Filipinas.
El fármaco, comercializado como TYMLOS® en los EE. UU., está indicado para el tratamiento de la osteoporosis en mujeres posmenopáusicas y hombres con un mayor riesgo de fracturas. Según los términos del acuerdo, Radius recibirá un pago inicial, hitos regulatorios y comerciales, además de regalías escalonadas sobre las ventas netas.
La asociación tiene como objetivo aprovechar la fuerte presencia comercial de Pharmanovia en la APAC, especialmente en China, donde mantienen una plataforma comercial líder en osteoporosis.
Radius Pharmaceuticals는 Pharmanovia와의 라이선스 계약을 발표하여 아시아 태평양 주요 시장에서 골다공증 치료를 위한 뼈 형성 제제인 abaloparatide를 상용화하게 됩니다. 이 계약은 중국을 포함해 싱가포르, 태국, 인도네시아, 베트남, 타이완, 홍콩, 말레이시아, 마카오, 필리핀 등 아홉 개의 영토를 포함합니다.
이 약물은 미국에서 TYMLOS®로 판매되며, 폐경 후 여성과 골절 위험이 증가한 남성의 골다공증 치료에 적합합니다. 계약 조건에 따라 Radius는 선불금, 규제 및 상업적 이정표, 그리고 순매출에 따른 단계별 로열티를 받게 됩니다.
이 파트너십은 Pharmanovia의 아시아 태평양 지역에서의 강력한 상업적 입지를 활용하는 것을 목표로 하고 있으며, 특히 중국에서 골다공증 상업 플랫폼을 선도하고 있습니다.
Radius Pharmaceuticals a annoncé un accord de licence avec Pharmanovia pour la commercialisation de abaloparatide, un agent formant l'os pour le traitement de l'ostéoporose, sur les principaux marchés de la région Asie-Pacifique. L'accord couvre la Chine et neuf autres territoires, dont Singapour, la Thaïlande, l'Indonésie, le Vietnam, Taïwan, Hong Kong, la Malaisie, Macao et les Philippines.
Le médicament, commercialisé sous le nom de TYMLOS® aux États-Unis, est indiqué pour le traitement de l'ostéoporose chez les femmes ménopausées et les hommes présentant un risque accru de fractures. Selon les termes de l'accord, Radius recevra un paiement initial, des jalons réglementaires et commerciaux, ainsi que des redevances échelonnées sur les ventes nettes.
Le partenariat vise à tirer parti de la forte présence commerciale de Pharmanovia dans la région APAC, en particulier en Chine, où elle dispose d'une plateforme commerciale leader dans le domaine de l'ostéoporose.
Radius Pharmaceuticals hat eine Lizenzvereinbarung mit Pharmanovia bekannt gegeben, um abaloparatide - ein knochenbildendes Mittel zur Behandlung von Osteoporose - in wichtigen Märkten des asiatisch-pazifischen Raums zu vermarkten. Die Vereinbarung umfasst China und neun weitere Gebiete, darunter Singapur, Thailand, Indonesien, Vietnam, Taiwan, Hongkong, Malaysia, Macau und die Philippinen.
Das Medikament wird in den USA als TYMLOS® vermarktet und ist zur Behandlung von Osteoporose bei postmenopausalen Frauen und Männern mit erhöhtem Frakturrisiko angezeigt. Laut den Vereinbarungen wird Radius eine Vorauszahlung, regulatorische und kommerzielle Meilensteine sowie gestaffelte Tantiemen auf den Nettoumsatz erhalten.
Die Partnerschaft zielt darauf ab, die starke kommerzielle Präsenz von Pharmanovia in der APAC, insbesondere in China, zu nutzen, wo sie eine führende kommerzielle Plattform für Osteoporose unterhalten.
- New licensing agreement expanding market reach to 10 Asia Pacific territories
- Company to receive upfront payment, milestone payments, and tiered royalties
- Access to Pharmanovia's established commercial platform in APAC region
- None.
Insights
The licensing agreement with Pharmanovia represents a strategic expansion into the lucrative Asia Pacific market, particularly China, which holds significant revenue potential given its aging population and increasing osteoporosis prevalence. The deal structure, including upfront payment, milestone payments and tiered royalties, provides multiple revenue streams for Radius.
The APAC osteoporosis market is projected to grow at a CAGR of
For a company with a market cap of
Abaloparatide's expansion into APAC markets is particularly significant given the region's rapidly aging demographics and high osteoporosis burden. China alone has over 70 million osteoporosis patients, with only about
The partnership with Pharmanovia, leveraging their established osteoporosis commercial platform, could accelerate market penetration and patient access. Clinical data has demonstrated abaloparatide's efficacy in reducing vertebral fracture risk by
BOSTON, MA / ACCESSWIRE / January 2, 2025 / Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc. ("Radius" or the "Company"), a specialty biopharmaceutical company focused on bone health and related areas, announced today it has granted Pharmanovia the exclusive commercialization rights to abaloparatide, a novel bone forming agent indicated for the treatment of osteoporosis in postmenopausal women and men at increased risk of fractures. The licensing agreement covers markets in the Asia Pacific region, specifically China, Singapore, Thailand, Indonesia, Vietnam, Taiwan, Hong Kong, Malaysia, Macau and the Philippines. Abaloparatide is marketed in the U.S. by Radius under the tradename TYMLOS®.
"We are very pleased to enter into a partnership with Pharmanovia with the goal of making abaloparatide available to patients in additional global markets," said Scott Briggs, Chief Executive Officer of Radius. "This collaboration partners two companies that share a commitment to improving the lives of patients with osteoporosis. With Pharmanovia's expertise in osteoporosis and their proven track record of success in these territories, we can look forward to significantly expanding abaloparatide access to patients in need of osteoporosis treatment options."
"We are thrilled to expand our portfolio and bring to the Asia Pacific region such an important and innovative osteoporosis treatment," said James Burt, Chief Executive Officer of Pharmanovia. "This deal recognizes the strength of our commercial model in APAC, and China in particular, where we have one of the leading osteoporosis commercial platforms."
Under the terms of the Licensing Agreement, Radius would be eligible to receive an upfront payment as well as regulatory and commercial milestones plus tiered royalties on net sales.
About Radius:
Radius is a global biopharmaceutical company dedicated to transforming the future for underserved, global patient populations in bone health and related areas. Radius' lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration in April 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture, and in December 2022 to increase bone density in men with osteoporosis at high risk for fracture. Radius also has an exclusive licensing and distribution agreement for the U.S. rights to BINOSTO® (alendronate sodium) effervescent tablet for oral solution, expanding the Company's presence in bone health.
About Pharmanovia:
Pharmanovia is a global lifecycle management healthcare company. Our purpose is to make medicines fit for tomorrow, to improve the lives of patients globally. We do this by rediscovering, repurposing or re-engineering established medicines or by bringing to market novel medicines to improve patient outcomes and experiences. With a diverse and growing team in over 160 countries across the globe, we deliver high-quality solutions, ethically and sustainably, across our four core therapeutic areas - Endocrinology, Neurology, Cardiovascular and Oncology both in rare and established diseases or conditions.
Contacts:
Al Medwar: Senior Vice President, Business and Corporate Development, Radius
Email: CorporateCommunications@radiuspharm.com
SOURCE: Radius Health
View the original press release on accesswire.com
FAQ
What territories are included in the Radius (RDUS) licensing agreement with Pharmanovia?
What are the financial terms of Radius (RDUS) licensing deal with Pharmanovia?
What is the purpose of abaloparatide in Radius (RDUS) licensing agreement?
How is abaloparatide marketed by Radius (RDUS) in the United States?
